SR141342

SR141342 is the **active metabolite of eplivanserin**, a pharmaceutical small molecule[1]. Eplivanserin and its active metabolite SR141342 act as **selective serotonin 5-HT2A receptor antagonists**, investigated primarily for sleep disorders such as insomnia[1][4]. SR141342 itself is not a branded drug product but has been characterized in pharmacokinetic and mechanistic studies as the main circulating metabolite resulting from oral administration of eplivanserin[1]. Mechanistic relevance is based on antagonism of central serotonin receptors, which modulates sleep architecture and related CNS processes. Main developer and clinical trial sponsor for related studies was **Sanofi Synthelabo Recherche**[4].

Other names

SR141342SR-141342SR 141342